BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

July 22, 2013 7:00 AM UTC

Biogen Idec Inc. (NASDAQ:BIIB) was up $7.15 to $230.27 on Friday after FDA accepted a BLA and EMA accepted an MAA for Plegridy peginterferon beta-1a (BIIB017) to treat relapsing forms of multiple sclerosis (MS). The company submitted the BLA in May. The PDUFA date is not disclosed. Biogen Idec gained $3.93 on the week.

Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) was up $0.30 (12%) to $2.75 last week after FDA accepted for review a resubmitted NDA for Northera droxidopa to treat symptomatic neurogenic orthostatic hypotension (NOH). The PDUFA date is Jan. 3, 2014...